en · de · es · pt
methods-notes.peptides6908.com › Guide › Background And Chemical Profile — Worked Examples

Background And Chemical Profile — Worked Examples

By Editorial Desk · published 2026-03-18 · last reviewed 2026-04-05 · Guide

The short version of melanotan-2 fits in a sentence. The long version — which is the one that helps — is below.

Reviewed 2026-04-05. Anything still debated is marked as such rather than presented as settled.

Background and Chemical Profile

Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.

Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.

Melanotan-2 Identity and Receptor Pharmacology

Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.

Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.

Melanotan-2 at a glance

PropertyValueNotes
Molecular classSynthetic cyclic heptapeptideAnalog of alpha-MSH with an internal lactam bridge
Molecular weightApproximately 1024 daltonsFree base value; salt forms differ
AppearanceWhite to off-white powderUsually supplied as a lyophilized solid
SolubilityFreely soluble in waterPoorly soluble in nonpolar solvents
Typical storage−20 °C, dry, protected from lightRepeated freeze-thaw cycles degrade peptides

Melanotan-2 Identity And Regulatory Status

Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.

Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.

Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.

Related pages on this site

Background and Mechanism of Melanotan-2

Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.

Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.

Background from the literature

A common issue with animal vaccination is that it interferes with immunological tests as both infection and vaccination can result in antibodies against an antigen being made. To solve this issue, special marker vaccines are created using pathogen strains carrying at least one epitope less than the equivalent wild microorganism. An accompanying diagnostic test that detects the antibody against that epitope assists in identifying whether the animal has been vaccinated or not. They are also called "DIVA vaccines". The first marker vaccines and companion diagnostic tests were developed by J. T. van Oirschot and colleagues at the Central Veterinary Institute in Lelystad, The Netherlands. They found that some existing vaccines against pseudorabies (also termed Aujeszky's disease) had deletions in their viral genome (among which was the gE gene). Monoclonal antibodies were produced against that deletion and selected to develop an ELISA that demonstrated antibodies against gE. In addition, novel genetically engineered gE-negative vaccines were constructed. Along the same lines, DIVA vaccines and companion diagnostic tests against bovine herpesvirus 1 infections have been developed. The DIVA strategy has been applied in various countries to successfully eradicate pseudorabies virus from those countries. Swine populations were intensively vaccinated and monitored by the companion diagnostic test and, subsequently, the infected pigs were removed from the population. Bovine herpesvirus 1 DIVA vaccines are widely used in European BoHV-1 control and eradication programmes.

=== Pet food === In the US, Turkestan cockroaches are sometimes kept to feed to pet reptiles and other insectivores, chosen partly because they can't climb smooth surfaces and don't burrow. Cockroaches have been replacing crickets, the most popular feeder insect for decades, due to the cricket's noise, odor, short lifespan, and expense. Turkestan cockroaches are a popular choice of species, and are readily available for sale over the Internet, which may hasten their spread to new habitats. Although reliable information on specific dietary requirements of insectivores is scant, Turkestan cockroaches provide a high-protein, low fat nutrition composition similar to crickets, more so than mealworms or superworm larvae provide. The gut contents of the cockroach, depending on its diet, may provide essential nutrients unavailable from a cockroach with an empty gut. In a study of commercially ordered specimens, small second instar nymphs (0.9–1.3 cm or 0.35–0.51 in) consisted of 21% dry matter, made of 76% crude protein and 14% crude fat, while medium third instar nymphs (1.3-1.9 cm) consisted of 28% dry matter, made of 53% crude protein and 27% crude fat. Mineral content is well represented except for a low calcium:phosphorus ratio typical in cockroaches, and calcium supplementation may be advisable. Vitamin A and E content was relatively low, and is generally significantly higher in free-ranging cockroaches.

=== Efficacy === 2,6-Dichloro-1,4-benzoquinone is primarily used in research due to its ability to participate in electron transfer reactions. In photosynthesis, it can act as an artificial electron acceptor in photosystem II. Researchers can measure and analyse electron transport activity in chloroplasts and other photosynthetic systems. The ability to accept electrons in place of natural quinones makes the compound useful for investigating the mechanisms of photosynthetic energy conversion and for evaluating the effects of inhibitors or environmental stress on photosynthetic organisms. In addition, 2,6-DCBQ can inhibit enzymes such as acetylcholinesterase in laboratory experiments and may exhibit antimicrobial or algal toxicity due to its reactive quinone structure. These characteristics are mainly of research interest rather than therapeutic application.

and Baltimore in August 2025, a spokesperson for Moore conceded that the project "had challenges that were insurmountable", but said that the Moore administration would continue working with the FRA on future transportation projects.

Sources: en.wikipedia.org

Reference notes

Atomic mass (ma or m) is the mass of a single atom. The atomic mass mostly comes from the combined mass of the protons and neutrons in the nucleus, with minor contributions from the electrons and nuclear binding energy. The atomic mass of atoms, ions, or atomic nuclei is slightly less than the sum of the masses of their constituent protons, neutrons, and electrons, due to mass defect (explained by mass–energy equivalence: E = mc2). Atomic mass is often measured in dalton (Da) (a.k.a. unified atomic mass unit (u)). One dalton is equal to ⁠+1/12⁠ the mass of a carbon-12 atom in its natural state, given by the atomic mass constant mu = m(12C)/12 = 1 Da, where m(12C) is the atomic mass of carbon-12. Thus, the numerical value of the atomic mass of a nuclide when expressed in daltons is close to its mass number. The relative isotopic mass (see section below) can be obtained by dividing the atomic mass ma of an isotope by the atomic mass constant mu, yielding a dimensionless value. Thus, the atomic mass of a carbon-12 atom m(12C) is 12 Da by definition, but the relative isotopic mass of a carbon-12 atom Ar(12C) is simply 12. The sum of relative isotopic masses of all atoms in a molecule is the relative molecular mass. The atomic mass of an isotope and the relative isotopic mass refers to a certain specific isotope of an element. Because substances are usually not isotopically pure, it is convenient to use the elemental atomic mass which is the average atomic mass of an element, weighted by the abundance of the isotopes.

When two atoms are displaced, it is referred to as a "twist" pucker, in reference to the zigzag orientation. In an "endo" pucker, the major displacement of atoms is on the β-face, the same side as the C4'-C5' bond and the base. In an "exo" pucker, the major displacement of atoms is on the α-face, on the opposite side of the ring. The major forms of ribose are the 3'-endo pucker (commonly adopted by RNA and A-form DNA) and 2'-endo pucker (commonly adopted by B-form DNA). These ring puckers are developed from changes in ring torsion angles; there are infinite combinations of angles so therefore, there is an infinite number of transposable pucker conformations, each separated by disparate activation energies.

When transmembrane proteins are translated from RNA they have start-transfer-sequences and stop-transfer-sequences before their posttranslational modifications occurs. The start-transfer-sequence is used to recruit a signal recognition particle(SRP) which consequently stops translation until it binds to a SRP-receptor on the surface of the lipid bilayer. Translocons are channels in the membrane which allow proteins to be moved across the membrane and the Ribosome synthesizes the polypeptide directly through it. The start-transfer-sequence is attached to the Translocon and is cleaved posttranslationally along with the stop-transfer-sequence. Many other complex pathways for embedding proteins exist, specific to eukaryotes and prokaryotes respectively.

Representative values of this ratio for a few liquids are given in Table 1. The conclusion is that quantum effects are important for liquids at low temperatures and with small molecular mass. For dynamic processes, there is an additional timescale constraint:

==== Surgery ==== Tranexamic acid is sometimes used in orthopedic surgery to reduce blood loss, to the extent of reducing or altogether abolishing the need for perioperative blood transfusion. It is of proven value in clearing the field of surgery and reducing blood loss when given before or after surgery. Drain and number of transfusions are reduced. In surgical corrections of craniosynostosis in children it reduces the need for blood transfusions. In spinal surgery (e.g., scoliosis), correction with posterior spinal fusion using instrumentation, to prevent excessive blood loss. In cardiac surgery, both with and without cardiopulmonary bypass (e.g., coronary artery bypass surgery), it is used to prevent excessive blood loss.

Sources: en.wikipedia.org

Frequently asked questions

What is melanotan-2?

It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.

How does it differ from melanotan-1?

Melanotan-1, also called afamelanotide, is a shorter linear analog with a different amino acid sequence and no lactam ring. It has been evaluated in formal clinical programs, while melanotan-2 has not. The two are distinct molecules and are not interchangeable.

Is it the same as bremelanotide?

No. Bremelanotide is a related but distinct cyclic peptide that reached approved status for one specific clinical indication. Melanotan-2 is a separate molecule with its own sequence and properties. Shared ancestry in the melanocortin family does not make them the same substance.

What is melanotan-2 chemically?

It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.

Network